These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29089725)

  • 21. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
    Tireli D; He J; Nordling MM; Wienecke T
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The first experience with dabigatran antidote in the University Hospital Pilsen].
    Šlechtová J; Hajšmanová Z; Lavičková A; Šigutová P
    Cas Lek Cesk; 2016; 155(8):442-444. PubMed ID: 28098476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
    Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
    J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
    Lu VM; Phan K; Rao PJ; Sharma SV; Kasper EM
    Clin Neurol Neurosurg; 2019 Jun; 181():76-81. PubMed ID: 31015061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
    Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
    Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke.
    von Wowern F; Brizzi M; Holst J
    Eur J Case Rep Intern Med; 2017; 4(4):000569. PubMed ID: 30755937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
    Jarrett JB; Gimbar RP
    Am Fam Physician; 2017 Jun; 95(12):798-800. PubMed ID: 28671421
    [No Abstract]   [Full Text] [Related]  

  • 30. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
    Athavale A; Jamshidi N; Roberts DM
    Clin Toxicol (Phila); 2020 Aug; 58(8):789-800. PubMed ID: 32267185
    [No Abstract]   [Full Text] [Related]  

  • 31. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-guided residence time optimization of a dabigatran reversal agent.
    Schiele F; van Ryn J; Litzenburger T; Ritter M; Seeliger D; Nar H
    MAbs; 2015; 7(5):871-80. PubMed ID: 26047352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
    Meyer D; Chu F; Derry K; Hailey L
    J Clin Neurosci; 2019 Jan; 59():355-357. PubMed ID: 30309801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
    Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Royle G; Sellke FW; Stangier J; Steiner T; Verhamme P; Wang B; Young L; Weitz JI
    N Engl J Med; 2017 Aug; 377(5):431-441. PubMed ID: 28693366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
    Yasaka M; Ikushima I; Harada A; Imazu S; Taniguchi A; Norris S; Gansser D; Stangier J; Schmohl M; Reilly PA
    Res Pract Thromb Haemost; 2017 Oct; 1(2):202-215. PubMed ID: 30046691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.